Major Study of Combination HIV Prevention Gets Underway
September 30, 2013. The HIV Prevention Trials Network (HPTN) is pleased to announce the launch of the HPTN 071 study (PopARTPopulation Effects of Antiretroviral Therapy to Reduce HIV Transmission). This study is being conducted in South Africa and Zambia and will determine the impact of a combined package of several HIV prevention interventions in reducing the number of new HIV infections in communities.
The trial is funded primarily by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) administered by the Office of the Global AIDS Coordinator. The study involves 21 communities with a total population of 1.2 million in the Western Cape in South Africa and Zambia.
The prevention package includes a universal HIV test and treat model (UTT), with annual home-based HIV testing, linking those found to be HIV positive to care and offering immediate antiretroviral therapy (ART) for all HIV-infected adults, irrespective of CD4 count.
HPTN 071 (PopART) is a fantastic opportunity for Stellenbosch University to work together in close partnership with health departments, non-governmental organizations and communities on a trial which has the potential to influence global policy and find novel ways of reducing the transmission of HIV, said Nulda Beyers, HPTN 071 (PopART) Site Principal Investigator in South Africa and the Director of the Desmond Tutu TB Centre at Stellenbosch University.
The head of department of health at the Western Cape government, Professor Craig Househam, said he fully supported the trial.
We are keen to work together to try to turn the tap off on HIV and break the cycle of transmission, he said.
The HPTN 071 (PopART) study will aim to deliver the prevention package to all households within a community to enhance coverage and thereby reduce new HIV infections at the population level.
There is a very strong rationale for test-and-treat as a new approach to HIV prevention, said Richard Hayes, HPTN 071 (PopART) Principal Investigator and Professor of Epidemiology and International Health at the London School of Hygiene and Tropical Medicine.
The study will help determine whether this approach can be delivered on a wide scale in sub-Saharan Africa with high uptake and coverage, and what impact this will have on HIV incidence at the population level.
Specially trained community health workers will play a key role and will result in significant job creation. A total of 336 community health workers in the Western Cape have been trained as Community HIV Care Providers on HIV Counseling and Testing and finger prick testing. By the end of the first year of the trial, 464 staff members are expected to be trained in the Intervention and Research component of the trial in the Western Cape, said Blia Yang, Project Manager of the HPTN 071 PopART Intervention for South Africa.
Twelve of the study sites will be in Zambia and nine in the Western Cape in South Africa, with six in the Cape Town metro.
The communities involved in the study were randomly assigned to one of three groups (arms) in a public randomization ceremony in Cape Town earlier this year. The full HPTN 071 (PopART) intervention package will be offered to seven communities (Arm A), another seven communities will receive the full package but with ART initiated according to current national guidelines (Arm B) and the remaining seven communities will receive current standard of care for both testing and treatment (Arm C).
To measure the impact of the intervention, a population cohort consisting of a representative sample of 2,500 adults will be recruited from the general population of each community (a total of 52,500 across all 21 communities) and will be followed up annually for three years. The occurrence of new HIV infections in these communities will be compared between the three study arms to determine the effect of the PopART interventions.
The full PopART HIV prevention package that will be offered includes:
House-to-house voluntary HIV testing offered at annual intervals
Linkage of HIV-infected individuals to HIV care
Promotion of voluntary medical circumcision for HIV-uninfected men
Promotion of steps to prevent mother-to-child HIV transmission
Referral of individuals with symptoms suggestive of TB or sexually transmitted infections for diagnosis and care at the local health center
HPTN 071 (PopART) builds upon previous research that bolsters the argument for this prevention approach. HPTN 052 was the first randomized trial to demonstrate that treating an HIV-infected individual with ART can significantly reduce the risk of sexual transmission of HIV to an uninfected partner, and the HPTN study Project Accept (HPTN 043) found that adding community mobilization and mobile HIV counseling and testing to facility-based testing can improve rates of testing in rural communities compared to facility-based testing alone. In a recent observational study in KwaZulu-Natal, expansion of HIV treatment (according to prevailing South African guidelines) at advanced stage of HIV disease was also shown to be associated with a reduction in HIV incidence.
HPTN 071 (PopART) is a natural extension of HPTNs HIV prevention research portfolio as it relates to integrated strategies for HIV prevention, said Dr. Wafaa El-Sadr, HPTN Principal Investigator. The findings from HPTN 071 (PopART) will be critical for policy makers as this study will determine whether such an HIV prevention package will work at population level and whether it is cost effective.
This study represents an important research milestone, said Helen Ayles, HPTN 071 (PopART) Site Principal Investigator in Zambia and ZAMBART Project Coordinator. It represents another critical step in the global effort to identify combination prevention strategies that can significantly reduce HIV incidence in populations that bear a disproportionate burden of HIV infection.
The study is in line with the goals of the U.S. Presidents Emergency Plan for AIDS Relief (PEPFAR) which aims to match interventions and investments with epidemiological trends and needs in order to improve impact.
The study is being conducted by the National Institutes of Health-funded HIV Prevention Trials Network (HPTN). The study is led by investigators at the London School of Hygiene and Tropical Medicine in collaboration with Imperial College London, the Zambia AIDS Related Tuberculosis Project (ZAMBART) and the Desmond Tutu TB Centre at Stellenbosch University, South Africa.
The study is sponsored by NIHs National Institute of Allergy and Infectious Diseases (NIAID), with funding from PEPFAR. Additional funding is provided by the International Initiative for Impact Evaluation with support from the Bill & Melinda Gates Foundation, as well as by NIAID, the National Institute on Drug Abuse and the National Institute of Mental Health, all part of NIH.